Bernina BioInvest

Founded in 2018, Versameb is a biotechnology company based in Basel, Switzerland. It specializes in developing RNA-based drugs for modulating protein expression and cellular targeting. The company's proprietary platform, VERSagile, optimizes functional RNA application across various disease contexts. Its pipeline includes lead programs in stress urinary incontinence, solid tumors, and rare diseases.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Founded in 2018, Versameb is a biotechnology company based in Basel, Switzerland. It specializes in developing RNA-based drugs for modulating protein expression and cellular targeting. The company's proprietary platform, VERSagile, optimizes functional RNA application across various disease contexts. Its pipeline includes lead programs in stress urinary incontinence, solid tumors, and rare diseases.

ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.

ImmunOs Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel human immunomodulatory proteins and therapies for cancer and autoimmune diseases. The company aims to enhance cancer treatment by leveraging proteins with direct anti-tumor effects that remodel the tumor microenvironment and by developing antibodies that block activation of specific HLA molecules implicated in autoimmune conditions. Founded in 2014 and based in Schlieren, Switzerland, ImmunOs Therapeutics pursues next-generation therapeutics intended to improve outcomes for patients with serious diseases.

ARTIDIS is a Basel, Switzerland-based company that develops tissue diagnostic solutions for personalized cancer therapy. It focuses on Automated Reliable Tissue Diagnostics, a nanomechanical diagnostic tool that analyzes biopsy tissue to distinguish benign from malignant tissue within hours and to assess tumor aggressiveness based on tissue stiffness signatures. The platform combines a tissue analysis device with software that integrates clinical data and enables non-destructive biopsy analysis at the point of care, using AI-powered analysis to generate actionable treatment insights. While optimized for oncology, the technology can analyze other living tissue.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Founded in 2018, Versameb is a biotechnology company based in Basel, Switzerland. It specializes in developing RNA-based drugs for modulating protein expression and cellular targeting. The company's proprietary platform, VERSagile, optimizes functional RNA application across various disease contexts. Its pipeline includes lead programs in stress urinary incontinence, solid tumors, and rare diseases.

InterAx Biotech Ltd is a biotechnology company based in Villigen, Switzerland, focused on developing a platform for the discovery of functionally selective drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 2016, the company integrates bioanalytical methods and computational pharmacology to assist in drug candidate design and selection. Its innovative platform combines high-throughput biochemical screening with artificial intelligence and mathematical modeling of cell signaling, facilitating the identification and optimization of drug candidates for various diseases, including those associated with orphan GPCRs. Through its advanced approach, InterAx Biotech aims to improve drug efficacy while reducing side effects, contributing to the healthcare industry's efforts to discover safer and more effective treatments.

Founded in 2018, Versameb is a biotechnology company based in Basel, Switzerland. It specializes in developing RNA-based drugs for modulating protein expression and cellular targeting. The company's proprietary platform, VERSagile, optimizes functional RNA application across various disease contexts. Its pipeline includes lead programs in stress urinary incontinence, solid tumors, and rare diseases.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.